NCIt definition : An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed
against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4),
with immune checkpoint inhibitory and antineoplastic activities. Upon administration,
anti-CTLA-4 monoclonal antibody botensilimab binds to CTLA-4 expressed on T-cells
and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to
a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4,
an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role
in the downregulation of the immune system. The engineered Fc domain increases the
stability and half-life of the antibody.;
UNII : 1Z5YC3ME5N;
CAS number : 2408310-37-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2408310-37-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)